Shire has a 60-year-long heritage of leadership in healthcare.1
Shire is a global leader in the development and manufacturing of therapies for haematology. Shire has a decades-long heritage of bringing innovative therapeutics to the haemophilia community. We develop a deep understanding of each patient's journey in order to deliver transformative and personalised therapies to improve the lives of patients with haemophilia and other bleeding conditions.
Because patients are at the center of everything we do, we work with public and private partners in communities around the world to expand access to treatments and elevate the standards of care.
At Shire, we believe in a world with endless possibilities for patients, where they can dream big and live life to the fullest.
1. Baxter International Inc. Baxter history. http://www.baxter.com/about_baxter/company_profile/history.html. Accessed May 14, 2015. 2. Baxter International Inc. Baxter BioScience fact sheet. http://www.baxter.com/press_room/factsheets/bioscience_factsheet.html. Accessed May 14, 2015. 3. Baxter Healthcare Corporation. Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures [NCT01913405]. US National Institutes of Health Web site. https:// clinicaltrials.gov/ct2/show/NCT01913405. Accessed May 22, 2015. 4. Baxter Healthcare Corporation. Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) [NCT01410227]. US National Institutes of Health Web site. https://clinicaltrials.gov/ct2/show/NCT01410227?term=Pharmacokinetics%2C+Safety+and+Efficacy+of+
Recombinant+Von+Willebrand+Factor+%28rVWF%29+in+the+Treatment+of+Bleeding+Episodes+in+Von+Willebrand+Disease+%28VWD%29&rank=1. Accessed May 22, 2015. 5. Baxter Healthcare Corporation. Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B. US National Institutes of Health Web site [NCT01687608]. https://clinicaltrials.gov/ct2/ show/NCT01687608. Accessed May 22, 2015. 6. Baxter announces restructured agreement with Xenetic Biosciences, further bolstering its broad bleeding disorder pipeline [press release]. Deerfield, IL: Baxter International Inc., January 30, 2014. 7. Baxter BioScience announces positive phase III results for BAX 817, investigational recombinant treatment for hemophilia A and B patients with inhibitors [press release]. Deerfield, IL: Baxter International Inc.; March 13, 2015. 8. Data on file. Baxalta Incorporated.